BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26867890)

  • 1. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.
    Zhou R; Xu T; Nguyen QN; Liu Y; Yang J; Komaki R; Gomez DR; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):452-461. PubMed ID: 29174428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
    Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
    Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
    Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.
    Palma DA; Senan S; Tsujino K; Barriger RB; Rengan R; Moreno M; Bradley JD; Kim TH; Ramella S; Marks LB; De Petris L; Stitt L; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):444-50. PubMed ID: 22682812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary function parameters as prognostic factors in advanced non-small cell lung cancer.
    Rančić M; Ristić L; Rančić S; Radović M; Ćirić Z
    Med Glas (Zenica); 2014 Feb; 11(1):58-65. PubMed ID: 24496342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
    De Petris L; Lax I; Sirzén F; Friesland S
    Med Oncol; 2005; 22(4):375-81. PubMed ID: 16260855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group.
    Ostheimer C; Mäurer M; Ebert N; Schmitt D; Krug D; Baumann R; Henkenberens C; Giordano FA; Sautter L; López G; Fleischmann DF; Niyazi M; Käsmann L; Kaul D; Thieme AH; Billiet C; Dobiasch S; Arnold CR; Oertel M; Haussmann J; Gauer T; Goy Y; Suess C; Ziegler S; Panje CM; Baues C; Trommer M; Skripcak T; Medenwald D
    Strahlenther Onkol; 2021 May; 197(5):385-395. PubMed ID: 33410959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy.
    Chen C; Uyterlinde W; Sonke JJ; de Bois J; van den Heuvel M; Belderbos J
    Radiother Oncol; 2013 Aug; 108(2):337-41. PubMed ID: 24074814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis.
    Yu Y; Guan H; Xing LG; Xiang YB
    Clin Ther; 2015 Oct; 37(10):2256-66. PubMed ID: 26293808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy.
    Jabbour SK; Kim S; Haider SA; Xu X; Wu A; Surakanti S; Aisner J; Langenfeld J; Yue NJ; Haffty BG; Zou W
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):627-33. PubMed ID: 26068495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy.
    Stinchcombe TE; Morris DE; Moore DT; Bechtel JH; Halle JS; Mears A; Deschesne K; Rosenman JG; Socinski MA
    Lung Cancer; 2006 Apr; 52(1):67-74. PubMed ID: 16499996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent non-small-cell lung cancer after surgical resection.
    Lee NK; Moon SH; Kim TH; Han JY; Yun T; Kim HT; Lee HS; Kim MS; Lee JM; Cho KH; Lee JS
    Clin Lung Cancer; 2013 Jul; 14(4):399-406. PubMed ID: 23276823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Chen NB; Li QW; Zhu ZF; Wang YM; Cheng ZJ; Hui ZG; Guo SP; He HQ; Wang B; Huang XY; Li JB; Guo JY; Hu N; Ai XL; Zhou Y; Wang DQ; Liu FJ; Xie CM; Qiu B; Liu H
    Radiat Oncol; 2020 Nov; 15(1):260. PubMed ID: 33168045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer.
    Wiersma TG; Dahele M; Verbakel WF; van de Ven PM; de Haan PF; Smit EF; van Reij EJ; Slotman BJ; Senan S
    Lung Cancer; 2013 Apr; 80(1):62-7. PubMed ID: 23357464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.